Maruyama, Shoichi http://orcid.org/0000-0002-8858-632X
Kurasawa, Shimon
Hayashi, Terumasa
Nangaku, Masaomi
Narita, Ichiei
Hirakata, Hideki
Tanabe, Kenichiro
Morita, Satoshi
Tsubakihara, Yoshiharu
Imai, Enyu
Akizawa, Tadao
Hiramatsu, Takeyuki
Tamai, Hirofumi
Iida, Yoshiyasu
Naruse, Tomohiro
Oishi, Hideto
Uchida, Shunya
Shimizu, Hideaki
Morozumi, Kunio
Kurata, Hisashi
Hirawa, Nobuhito
Nishio, Saori
Yuzawa, Yukio
Mizutani, Makoto
Aoyama, Isao
Yoshida, Hideaki
Kaneda, Kouji
Suzuki, Satoshi
Adachi, Hiroki
Kinugasa, Eriko
Kurata, Kei
Morinaga, Hiroshi
Tsukamoto, Yusuke
Tsuruya, Kazuhiro
Ando, Ryoichi
Ichida, Shizunori
Tamura, Teiichi
Masaki, Takao
Wada, Takashi
Honda, Hirokazu
Yamamoto, Junichiro
Isaka, Yoshitaka
Muso, Eri
Komatsu, Yasuhiro
Ohashi, Norimi
Hara, Taiga
Ikeda, Kiyoshi
Okada, Kazuyoshi
Yoshida, Tetsuhiko
Okuda, Seiya
Suzuki, Hiromichi
Nakanishi, Takeshi
Higashi, Harumichi
Shirasaki, Arimasa
Endo, Shuichiro
Osawa, Yutaka
Aoyagi, Ryuji
Tomino, Yasuhiko
Akimoto, Tetsu
Watanabe, Tsuyoshi
Toyonaga, Jiro
Tanaka, Motoko
Ishibashi, Yoshitaka
Uezono, Shigehiro
Sakakibara, Masako
Yamazaki, Hajime
Takano, Hideki
Ikeda, Hirofumi
Takata, Takuma
Yamashita, Hiroshi
Yamagata, Kunihiro
Sato, Toshinobu
Yoshimura, Ashio
Tamagaki, Keiichi
Sonomura, Kazuhiro
Iguchi, Akira
Tamura, Masahito
Yasukawa, Ryota
Oku, Manei
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
https://doi.org/10.2215/cjn.08900719
Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
https://doi.org/10.1007/s10157-023-02362-w
Funding for this research was provided by:
Translational Informatics Research Center
Article History
Received: 16 March 2023
Accepted: 14 May 2023
First Online: 8 June 2023
Declarations
:
: Dr. Maruyama has received honoraria from Kyowa Kirin, Chugai, Astellas, and Mitsubishi Tanabe; grants and/or research funding from Kyowa Kirin, Chugai, Astellas, Mitsubishi Tanabe, and Torii. Dr. Kurasawa has received honoraria from Kyowa Kirin.
: The protocol was approved by the institutional review board of each participating center, in accordance with the principles of the Declaration of Helsinki; Ethical Guidelines on Clinical Studies of the Ministry of Health, Labour, and Welfare of Japan (Tokyo, Japan); and International Conference on Harmonization Good Clinical Practice guidelines.
: All participants in the study provided written informed consent.